secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scienture Holdings, Inc. (SCNX)
CIK:        0001382574
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001493152-25-011152
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scienture receives FDA approval for Arbli (losartan oral suspension); launch planned Q3 2025
--------------------------------------------------------------------------------

- FDA approves SCN-102 as Arbli (losartan potassium oral suspension), first liquid ready-to-use losartan in US.
- Arbli indicated for hypertension (age >6), stroke risk reduction, diabetic nephropathy.
- US losartan market $292M annual sales, 68M prescriptions (IQVIA Dec 2024); global $1.5B.
- Commercial launch expected Q3 2025; product has 18-month shelf life at room temp.
- Consulting agreement with Draper Inc. for IR/business dev: 100k shares initial + 100k/mo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382574/000149315225011152/0001493152-25-011152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382574/000149315225011152/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer